About


A global leader in cancer treatment

Sirtex Medical is a global healthcare business with offices in the US, Australia, Germany and Singapore, working to improve outcomes in people with cancer.

Our current lead product is a targeted radiation therapy for liver tumors called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied to treat patients with liver cancer at more than 1,300 medical centers in over 50 countries.

What are SIR-Spheres® Y-90 resin microspheres and how are they used?

SIR-Spheres® Y-90 resin microspheres is a prescription device for the treatment of inoperable liver tumors. It is a minimally invasive treatment that delivers high doses of high-energy beta radiation directly to the tumors.

This therapy is called Selective Internal Radiation Therapy (SIRT) and is performed using minimally invasive surgical techniques by an interventional radiologist.

By using the tumors’ blood supply, the microspheres selectively target liver tumors with a dose of radiation that is up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.

SIR-Spheres® Y-90 resin microspheres are approved for the treatment of inoperable liver tumors in Australia, the European Union, Argentina, Brazil, Canada and several countries in Asia, such as India, Indonesia, Malaysia, Myanmar, Singapore and South Korea.

In Taiwan SIR-Spheres Y-90 resin microspheres are approved for the treatment of metastatic liver tumors from primary colorectal cancer which are uncontrolled by IHAC and/or Chemotherapy. SIR-Spheres are unsuitable for use in patients with poor liver function such as those affected by Hepatitis B or suffering from hyperbilirubinemia. SIR-Spheres are also approved for use in the treatment of hepatocellular carcinoma in patients who are ineligible for ablation or resection.

In the United States, SIR-Spheres Y-90 resin microspheres received Premarket Approval (PMA) from the FDA and are indicated for the treatment of non-resectable metastatic liver tumors from primary colorectal cancer in combination with intrahepatic artery chemotherapy using floxuridine.

Disclaimer: Content on SIR-Spheres Y-90 resin microspheres is not intended for users in markets that do not have authorization for use.

 




Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×